An observational study in ACL Tears, sponsored by CONMED Corporation. Recruiting at 1 site in United States. Open to participants aged 14 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-23.
Sponsored by CONMED Corporation · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 176 studies in Anterior Cruciate Ligament Injuries with a site in United States — 44 open to participants now, 62 under way, 3 of them phase 3. Anterior Cruciate Ligament Injuries · United States.
Among the 176 studies in Anterior Cruciate Ligament Injuries with a site in United States, this one is the 8th largest by planned enrollment of the 24 observational ones that give a count, is one of 9 that started in 2025, is one of 24 observational ones, reaches primary completion later than 58 of the 61 other live ones, and was the 162nd registered.
627 studies on the registry are indexed under Anterior Cruciate Ligament Injuries; 193 are open to participants now.
Browse Anterior Cruciate Ligament Injuries studies →44 of the 176 studies in Anterior Cruciate Ligament Injuries with a site in United States are open now. Recruiting first, the newest first:
Stanford University · Sites in United States
Ages 13–17
Wake Forest University Health Sciences · Sites in United States
Ages 14–39
University of Michigan · Sites in United States
Ages 14–45
Spaulding Rehabilitation Hospital · Sites in United States
Ages 18–55
University of Arizona · Sites in United States
Ages 18–40
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 122 Anterior Cruciate Ligament Injuries studies recruiting now, 27 (22%) set no upper age limit and 92 (75%) stop at 75 or younger; 46 take children under 18; 21 take healthy volunteers.
This study: 14 Years to 70 Years · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
176 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 10 · Phase 3 9 · Phase 4 16
First in 2001; this study’s year is marked. 9 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 500 is above the median of 98 across 153 observational studies indexed under Anterior Cruciate Ligament Injuries.
Median enrollment 50 across the 152 interventional studies, 202 across the 24 observational. Of the 97 that completed or were terminated, 42 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 176 have an industry lead sponsor. The 10 most frequent:
CONMED Corporation is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
CONMED Corporation has 1 study filed under Anterior Cruciate Ligament Injuries — fewer than ten, so there is no comparison to draw.
22 of the studies in Anterior Cruciate Ligament Injuries with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05412381Phase 3Hospital for Special Surgery, New YorkPRP in ACLR to Prevent PTOA | 2026-12-31 |
| NCT06529692University of MichiganMichigan Split-belt Treadmill Training Program to Improve Long-Term Knee Biomechanics After ACL Reconstruction | 2026-12 |
| NCT05488054University Hospitals Cleveland Medical CenterMuscle O2 Saturation and Hemoglobin Levels During Rehabilitation From Arthroscopic Surgery | 2026-12 |
| NCT05965310Henry Ford Health SystemAnterior Cruciate Ligament Recovery With Virtual Psychological Intervention | 2027-01 |
| NCT03968913University of California, Los AngelesBiologic Therapy to Prevent Osteoarthritis After ACL Injury | 2027-01-30 |
Add all 22 to your calendar (.ics) → With an account.
Among the 176 studies in Anterior Cruciate Ligament Injuries with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This research study will evaluate mid-term clinical safety and performance outcomes of the BioBrace® Reinforced Implant when used to augment a tissue graft during anterior cruciate ligament (ACL) reconstruction.
This is a multi-center, single arm, open label registry investigating anterior cruciate ligament reconstruction (ACLR) procedures where the tissue graft is augmented with BioBrace®. Subjects meeting the inclusion/exclusion criteria will be enrolled retrospectively or prospectively. Clinical evaluations will be conducted at baseline (pre-operatively) and at 6 months, 1-, 2-, and 3-years post-operatively using various patient-reported outcome measures to assess pain, function, return to activity, and safety post-surgery.
Community surrounding participating hospitals / clinics.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
If the subject has already undergone ACLR within the past 24 months, subject must have at least two (2) of the following measures at baseline and 1 year post-operatively:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An anterior cruciate ligament reconstruction is performed and BioBrace is used to augment the tissue graft.
Device: Anterior cruciate ligament reconstruction with BioBrace® augmentation · Procedure: Arthroscopic anterior cruciate ligament reconstruction
An arthroscopic anterior cruciate ligament reconstruction (ACLR) will be performed and the tissue graft will be augmented with the BioBrace® Reinforced Implant. BioBrace® is intended for use in surgical procedures for reinforcement of soft tissue where weakness exists. It is a bioresorbable, biocomposite scaffold composed of a highly porous collagen sponge and reinforced with poly-L-lactic-acid (PLLA). When used in ACLRs, it is sutured alongside the tissue graft to augment and reinforce the graft construct. BioBrace® is designed to mechanically and biologically augment weakened or torn soft tissue and can be integrated into surgeons' standard of care ACL reconstruction techniques.
An arthroscopic anterior cruciate ligament reconstruction is performed using standard surgical procedure.
Improvement in Function
Improvement in function measured with International Knee Documentation Committee (IKDC) from baseline to 3 years post-surgery.
Time frame: 3 years post-op
Adverse Events
Evaluation of device-related adverse events
Time frame: Baseline, 6-months, 1-, 2-, and 3-years post-op
International Knee Documentation Committee (IKDC)
Patient-reported functional and activity status as assessed by International Knee Documentation Committee (IKDC)
Time frame: Baseline, 6 months, 1-, 2-years post-op
Knee Injury and Osteoarthritis Outcome Score Junior (KOOS, JR.)
Patient-reported functional and activity status as assessed by the following: Knee Injury and Osteoarthritis Outcome Score Junior (KOOS, JR.)
Time frame: Baseline, 6 months, 1-, 2-, and 3-years post-op
Patient-Reported Outcomes Measurement Information System (PROMIS-10)
Patient-reported functional and activity status as assessed by the following: Patient-Reported Outcomes Measurement Information System (PROMIS-10)
Time frame: Baseline, 6 months, 1-, 2-, and 3-years post-op
Tegner Activity Scale (TAS)
Patient-reported functional and activity status as assessed by: Tegner Activity Scale (TAS).
Time frame: Baseline, 6 months, 1-, 2-, and 3-years post-op
Anterior Cruciate Ligament - Return to Sport After Injury (ACL-RSI)
Patient-reported functional and activity status as assessed by the following: Anterior Cruciate Ligament - Return to Sport After Injury (ACL-RSI)
Time frame: 6 months, 1-, 2-, and 3-years post-op
Secondary Surgical Intervention(s)
The percentage of subjects who required additional surgical procedures following discharge from the BioBrace ACLR index procedure will be reported.
Time frame: 6 months, 1-, 2-, and 3-years post-op
Re-tear Rate
Re-tear rate of the surgically reconstructed ACL tissue graft augmented with BioBrace. The percentage of subjects who experienced a re-tear of the augmented ACL tissue graft will be reported.
Time frame: 6 months, 1-, 2-, and 3-years post-op
Started Apr 2025 (actual). Primary completion is estimated for Jun 2030, 62 months after the start.
Of 82 observational studies under Anterior Cruciate Ligament Injuries, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 76. This study's planned 62 months is above that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Anterior Cruciate Ligament Injuries →
CONMED Corporation